The immunologic balance: three cases of rituximab-associated melanoma.
Journal
Melanoma research
ISSN: 1473-5636
Titre abrégé: Melanoma Res
Pays: England
ID NLM: 9109623
Informations de publication
Date de publication:
01 02 2022
01 02 2022
Historique:
pubmed:
17
11
2021
medline:
24
3
2022
entrez:
16
11
2021
Statut:
ppublish
Résumé
Currently, there is no known clinical evidence that rituximab increases the rate of subsequent primary malignancies; however, some studies have raised the question of increased melanoma risk following rituximab treatment for non-Hodgkin lymphoma. We report three interesting cases of suspected rituximab-induced melanoma. We hypothesize that this association is secondary to rituximab-driven shifts in the immunologic balance. Based on these cases, it is possible that the number of post-rituximab melanoma cases is underreported. Further mechanistic research into individual cases and population-level studies are required to better define association and risk; however, given the increasing prevalence of oncologic and nononcologic rituximab use, awareness across all fields is essential.
Identifiants
pubmed: 34783721
doi: 10.1097/CMR.0000000000000799
pii: 00008390-202202000-00010
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
67-70Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22:7359–7368.
Neves H, Kwok HF. Recent advances in the field of anti-cancer immunotherapy. BBA Clin 2015; 3:280–288.
Aksoy S, Arslan C, Harputluoglu H, Dizdar O, Altundag K. Malignancies after rituximab treatment: just coincidence or more? J BUON 2011; 16:112–115.
Tao L, Clarke CA, Rosenberg AS, Advani RH, Jonas BA, Flowers CR, Keegan THM. Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era. Br J Haematol 2017; 178:72–80.
Fleury I, Chevret S, Pfreundschuh M, Salles G, Coiffier B, van Oers MH, et al. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. Ann Oncol 2016; 27:390–397.
Cengiz FP, Cetin G, Emiroglu N, Onsun N. Is rituximab therapy a risk factor for development of melanoma? Dermatol Ther 2020; 33:e13471.
Bajaj V, Vatve M, Longhi P, Iqbal A, Sripathy TK, Barrett P. Progression of melanoma after treatment with rituximab for lymphoma: cause or coincidence? J Am Acad Dermatol 2015; 72:AB174.
Peuvrel L, Chiffoleau A, Quéreux G, Brocard A, Saint-Jean M, Batz A, et al. Melanoma and rituximab: an incidental association? Dermatology 2013; 226:274–278.
Velter C, Pagès C, Schneider P, Osio A, Brice P, Lebbé C. Four cases of rituximab-associated melanoma. Melanoma Res 2014; 24:401–403.
Chiaruttini G, Mele S, Opzoomer J, Crescioli S, Ilieva KM, Lacy KE, Karagiannis SN. B cells and the humoral response in melanoma: the overlooked players of the tumor microenvironment. Oncoimmunology 2017; 6:e1294296.
Willsmore ZN, Harris RJ, Crescioli S, Hussein K, Kakkassery H, Thapa D, et al. B cells in patients with melanoma: implications for treatment with checkpoint inhibitor antibodies. Front Immunol 2020; 11:622442.
Avivi I, Stroopinsky D, Katz T. Anti-CD20 monoclonal antibodies: beyond B-cells. Blood Rev 2013; 27:217–223.
Stroopinsky D, Katz T, Rowe JM, Melamed D, Avivi I. Rituximab-induced direct inhibition of T-cell activation. Cancer Immunol Immunother 2012; 61:1233–1241.
Valero C, Lee M, Hoen D, Weiss K, Kelly DW, Adusumilli PS, et al. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat Commun 2021; 12:729.
Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000; 406:536–540.
Winkler JK, Schiller M, Bender C, Enk AH, Hassel JC. Rituximab as a therapeutic option for patients with advanced melanoma. Cancer Immunol Immunother 2018; 67:917–924.
Lam CJ, Curtis RE, Dores GM, Engels EA, Caporaso NE, Polliack A, et al. Risk factors for melanoma among survivors of non-Hodgkin lymphoma. J Clin Oncol 2015; 33:3096–3104.
Kumar V, Ailawadhi S, Bojanini L, Mehta A, Biswas S, Sher T, et al. Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer J 2019; 9:75.